ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

LGND vs BLTE // EV/EBITDA & P/E VALUATION

Ligand Pharmaceuticals Incorporated (NASDAQ) VS. Belite Bio Inc (NASDAQ) • 15-METRIC TALLY: LGND 5 — BLTE 0
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LGND VS. BLTE) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC LGND BLTE SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 3.00% -15.90% +18.90 LGND /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE 95.0x — — TIE /valuation <GO>
Free Cash Flow Yield 0.77% -0.61% +1.38 LGND /fcf-yield <GO>
Operating Margin 15.30% — — TIE /operating-margins <GO>
Net Profit Margin 46.40% — — TIE /net-margins <GO>
Revenue Growth (YoY) 60.40% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 8.40 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 8/9 2/9 +6.00 LGND /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 61.9 50.3 +11.60 LGND /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 1.07 — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 42.7x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $6.43B $6.23B $202.5M LGND /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR LGND REV BLTE REV LGND GROSS % BLTE GROSS % LGND FCF BLTE FCF
FY 2025 $268.1M $235.8M — — $48.9M -$37.1M
FY 2024 $167.1M $112.0M — — $95.2M -$29.4M
FY 2023 $131.3M $88.7M — — $43.7M -$29.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LGND // BETA 1.07
BLTE // BETA —